Invokana Lawsuit Plaintiffs Note FDA Adverse Event Reports And New Warning Label Requirements For Drug

April 01, 2016 – – TheProductLawyers.com reports on a concerning public announcement issued by The U.S. Food and Drug Administration on December 4th, 2015. The statement made note of new warning label requirements for new-generation, type-2 diabetes drug Invokana. Invokana is manufactured by Johnson & Johnson subsidiary Janssen Pharmaceuticals.

The FDA’s announcement followed the agency’s receipt of numerous adverse event reports detailing certain dangerous side effects which were appearing among patients using Invokana or similar SGLT2 class inhibitor drugs. One of the side effects specifically noted is termed diabetic ketoacidosis. This is a condition in which the body’s bloodstream contains a surplus of toxic acid (ketones). This medical condition is potentially life-threatening, and the agency is asking patients currently taking Invokana to carefully watch for symptoms which can include nausea and vomiting episodes, significant fatigue, abdominal pain, and trouble breathing.

The FDA also noted that, in further details of their adverse event reports, “All patients required hospitalization or treatment in an emergency department. In many cases, ketoacidosis was not immediately recognized because the blood glucose levels were below those typically expected for diabetic ketoacidosis. As a result, treatment of the ketoacidosis was delayed in some cases.”

Unfortunately, this is not the only dangerous side effect that Invokana has been connected to through FDA adverse event reports. The diabetes drug has also been linked to increased risk for the development of urinary tract infections (UTIs), which can progress into severe kidney and blood infections. The FDA has additionally noted that patients currently using the drug should remain aware of any pain or burning sensations during urination, in addition to other typical UTI symptoms.

The attorneys of Banville Law work daily to provide the general public with the latest important information on possible side effect risks surrounding Invokana and other drugs. To help inform the public, they sponsor an online resource website at TheProductLawyers.com. In addition, they are dedicated to helping ensure that patients who have taken Invokana or other SGLT2 class inhibitor drugs and who have suffered from adverse health events will be provided the opportunity to investigate their legal rights in the matter. Qualified parties interested in looking into their legal rights further are offered free consultations at this time from Banville Law.

To request more information or ask questions, contact Banville Law by calling 877-671-6480.

###

Contact TheProductLawyers.com:

Banville Law
877-671-6480
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60009025